Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

January 09, 2026 08:00 ET | Source: Medicines360

Medicines360 Acquires Global Licensing Rights to Innovative Maternal Health Technologies for Risk Identification and Management Throughout Pregnancy

Licensing of scientific discoveries from University of Cambridge and University of Edinburgh is aimed to speed translation and access to life-saving diagnostics for women worldwide. SAN FRANCISCO,...
January 09, 2026 08:00 ET | Source: Madrigal Pharmaceuticals, Inc.

Madrigal Expands its MASH Pipeline with Exclusive Global License Agreement for Ervogastat, a Phase 2 Oral DGAT-2 Inhibitor

Agreement expands Madrigal’s pipeline and strengthens its leadership in pioneering MASH therapiesDGAT-2 inhibition represents a complementary mechanism of action with Rezdiffra® (resmetirom) for...
January 09, 2026 07:05 ET | Source: uniQure Inc.

uniQure Announces Type A Meeting Scheduled with FDA

LEXINGTON, Mass. and AMSTERDAM, Jan. 09, 2026 (GLOBE NEWSWIRE) -- uniQure N.V. (NASDAQ: QURE), a leading gene therapy company advancing transformative therapies for patients with severe medical...
January 08, 2026 02:48 ET | Source: Nxera Pharma

Nxera Pharma Licenses Japan and Select Asia-Pacific Rights to Vamorolone for Duchenne Muscular Dystrophy from Santhera Pharmaceuticals

Vamorolone is approved and marketed as AGAMREE® for the treatment of Duchenne Muscular Dystrophy (DMD) in the US, European Union, UK and ChinaNew five-year data on vamorolone highlighted substantially...
January 05, 2026 20:00 ET | Source: Biogen Inc.

Biologics License Application for Subcutaneous Formulation of “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer’s Disease Accepted in China

TOKYO and CAMBRIDGE, Mass., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge,...
January 05, 2026 16:01 ET | Source: Cyclerion Therapeutics, Inc.

Cyclerion Therapeutics Announces Strategic Agreement with Medsteer and Progress Toward Initiating Phase 2 Proof-of-Concept Study for CYC-126 in Treatment-Resistant Depression

Cyclerion & Medsteer entered a strategic agreement to enable the integration of Medsteer's technology and know-how into CYC-126.
January 05, 2026 07:00 ET | Source: Skye Bioscience, Inc.

Halozyme and Skye Bioscience Announce Global Collaboration and License Agreement to Evaluate Nimacimab Co-Formulated with ENHANZE® for Obesity

SAN DIEGO, Jan. 05, 2026 (GLOBE NEWSWIRE) -- Halozyme Therapeutics, Inc. (Nasdaq: HALO) and Skye Bioscience, Inc. (Nasdaq: SKYE) today announced the companies entered into a non-exclusive global...
January 02, 2026 08:30 ET | Source: CDT Equity Inc.

CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy

CDT Engages NJS Foresight Bio-Advisory to Support Solid-Form Out-Licensing Strategy
December 29, 2025 16:54 ET | Source: MSB for Sale

MSBforSale.com Announces Strategic Partnership with B2Vault for Institutional Crypto Custody

Limassol, Cyprus, Dec. 29, 2025 (GLOBE NEWSWIRE) -- MSBforSale.com, a global leader in Money Service Business (MSB) licensing, compliance support, and crypto infrastructure solutions, today...
December 29, 2025 06:00 ET | Source: Adlai Nortye Ltd.

Adlai Nortye Enters Exclusive License Agreement with ASK Pharm for Pan-RAS (ON) Inhibitor AN9025 in Greater China

SINGAPORE and NORTH BRUNSWICK, N.J. and HANGZHOU, China, Dec. 29, 2025 (GLOBE NEWSWIRE) -- Adlai Nortye Ltd. (NASDAQ: ANL) (the “Company” or “Adlai Nortye”), a clinical-stage biotechnology company...